Bristol-Myers Squibb

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Bristol-Myers Squibb 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BMY

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. 

CEO
Christopher S. Boerner
CEOChristopher S. Boerner
Employees
34,100
Employees34,100
Headquarters
Princeton, New Jersey
HeadquartersPrinceton, New Jersey
Founded
1933
Founded1933
Employees
34,100
Employees34,100

BMY Key Statistics

Market cap
121.10B
Market cap121.10B
Price-Earnings ratio
19.46
Price-Earnings ratio19.46
Dividend yield
4.32%
Dividend yield4.32%
Average volume
13.65M
Average volume13.65M
High today
$60.56
High today$60.56
Low today
$57.37
Low today$57.37
Open price
$58.80
Open price$58.80
Volume
23.93M
Volume23.93M
52 Week high
$63.33
52 Week high$63.33
52 Week low
$42.52
52 Week low$42.52

Stock Snapshot

With a market cap of 121.1B, Bristol-Myers Squibb(BMY) trades at $59.34. The stock has a price-to-earnings ratio of 19.46 and currently yields dividends of 4.3%.

As of 2026-02-06, Bristol-Myers Squibb(BMY) stock has fluctuated between $57.37 and $60.56. The current price stands at $59.34, placing the stock +3.4% above today's low and -2.0% off the high.

The Bristol-Myers Squibb(BMY)'s current trading volume is 23.93M, compared to an average daily volume of 13.65M.

In the last year, Bristol-Myers Squibb(BMY) shares hit a 52-week high of $63.33 and a 52-week low of $42.52.

In the last year, Bristol-Myers Squibb(BMY) shares hit a 52-week high of $63.33 and a 52-week low of $42.52.

BMY News

TipRanks 6h
Bristol-Myers Squibb Bets On New Growth Engines

Bristol-Myers Squibb Company ((BMY)) has held its Q4 earnings call. Read on for the main highlights of the call. Claim 50% Off TipRanks Premium Unlock hedge fun...

TipRanks 10h
Reiterating Buy on Bristol-Myers Squibb: Milvexian’s Validated FXIa Mechanism and Underappreciated Stroke Prevention Upside Support $65 Target

Srikripa Devarakonda, an analyst from Truist Financial, maintained the Buy rating on Bristol-Myers Squibb. The associated price target remains the same with $65...

24/7 Wall St. 15h
Bristol Myers Just Crushed Earnings, and the Real Catalyst Hasn’t Even Hit Yet

Bristol Myers’ Growth Portfolio surged 16% to $7.4B in Q4 while Legacy Portfolio fell 15% on generic competition. Bristol Myers Squibb (BMY) guided 2026 revenu...

Bristol Myers Just Crushed Earnings, and the Real Catalyst Hasn’t Even Hit Yet

Analyst ratings

60%

of 30 ratings
Buy
36.7%
Hold
60%
Sell
3.3%

More BMY News

TipRanks 18h
Bristol Myers Squibb Posts 2025 Results, Raises Dividend

Bristol-Myers Squibb ( (BMY) ) has provided an update. On February 5, 2026, Bristol Myers Squibb reported its fourth-quarter and full-year 2025 financial resul...

Nasdaq 18h
Bristol-Myers Squibb Guides FY26 Above Estimates - Update

(RTTNews) - While reporting financial results for the fourth quarter on Thursday, Bristol-Myers Squibb Co. (BMY) initiated its adjusted earnings and revenue gro...

Bristol-Myers Squibb Guides FY26 Above Estimates - Update
Simply Wall St 1d
Bristol-Myers Squibb Expands RNA And Cell Therapy Pipeline With New Deals

Bristol-Myers Squibb (NYSE:BMY) has agreed to acquire Orbital Therapeutics to expand its RNA-based therapies portfolio for cancer and autoimmune diseases. The...

Bristol-Myers Squibb Expands RNA And Cell Therapy Pipeline With New Deals
Simply Wall St 2d
Bristol-Myers Weighs RNA Expansion Against Sprycel Generic Pressures

Bristol-Myers Squibb (NYSE:BMY) agreed to acquire Orbital Therapeutics, adding RNA-based therapies for cancer and autoimmune diseases to its pipeline. Lupin la...

Bristol-Myers Weighs RNA Expansion Against Sprycel Generic Pressures
Simply Wall St 6d
Bristol-Myers Squibb Cancer And AI Deals Put Valuation In Focus

Bristol-Myers Squibb, NYSE:BMY, has entered a collaboration with Janux Therapeutics to co-develop a tumor-activated cancer therapy targeting solid tumors. The...

Bristol-Myers Squibb Cancer And AI Deals Put Valuation In Focus
TipRanks 7d
BioNTech and Bristol-Myers Squibb Advance Pumitamig Trial in Aggressive Brain Cancer

Bristol-Myers Squibb Company (BMY), Biontech Se Sponsored Adr (BNTX) announced an update on their ongoing clinical study. Study Overview BioNTech and Bristol-...

Simply Wall St 7d
A Look At Bristol Myers Squibb Valuation After Recent Share Price Momentum

Bristol-Myers Squibb (BMY) is back on many investors’ radar after recent share price moves and fresh scrutiny of its fundamentals, including revenue of US$48.0b...

A Look At Bristol Myers Squibb Valuation After Recent Share Price Momentum

People also own

Based on the portfolios of people who own BMY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.